Pure Endoscopic Transsphenoidal Surgery for Functional Pituitary Adenomas: Outcomes with Cushing's Disease
Overview
Authors
Affiliations
Background: This study was performed to examine patient outcomes following pure endoscopic transsphenoidal surgery (ETS) for Cushing's disease (CD).
Method: We studied 64 consecutive patients who underwent 69 endoscopic transsphenoidal procedures. Radiological evaluation comprised detailed examination of preoperative magnetic resonance images (MRI), including positron emission tomography (PET) for select cases. Inferior petrosal sinus sampling (IPSS) was not performed for any patient. Remission was defined by the presence of hypocortisolemia with requirement for steroid replacement therapy or eucortisolemia with suppression to <1.8 μg/dl after 1 mg dexamethasone on evaluation at least 3 months after surgery.
Results: Preoperative MRI was abnormal in 87.5 % of cases and included 11 macroadenomas (17.2 %). PET was used to localize the adenoma in four cases. For microadenomas, operative procedures executed were as follows: selective adenomectomy (n = 15), enlarged adenomectomy (n = 21) and subtotal/hemihypophysectomy (n = 17). Overall, pathological confirmation of an adenoma was possible in 58 patients (90.6 %). Forty-nine patients (76.6 %) developed hypocortisolemia (<5 μg/dl) in the early postoperative period. Mean follow-up was 20 months (range 6-18 months). Remission was confirmed in 79.7 % of the 59 cases followed up for >3 months and was superior for microadenomas (86.4 %) versus macroadenomas (55.6 %) and equivocal MRI adenomas (66.7 %). Postoperative CSF rhinorrhea occurred in five patients, and new endocrine deficits were noted in 17.1 % patients. A nadir postoperative cortisol <2 μg/dl in the 1st week after surgery was highly predictive of remission (p = 0.001).
Conclusion: ETS allows for enhanced intrasellar identification of adenomatous tissue, providing remission rates that are comparable to traditional microsurgery for CD. The best predictor of remission remains induction of profound hypocortisolemia in the early postoperative period.
Retrospective analysis of the outcomes of endoscopic transsphenoidal surgery for Cushing's disease.
Srivastava A, Dobriyal A, Randhawa A, Jain P, Agrawal S, Verma J Surg Neurol Int. 2024; 15:240.
PMID: 39108389 PMC: 11301792. DOI: 10.25259/SNI_278_2024.
Hanalioglu S, Gurses M, Gecici N, Baylarov B, Isikay I, Gurlek A Pituitary. 2024; 27(3):259-268.
PMID: 38748309 PMC: 11150181. DOI: 10.1007/s11102-024-01396-x.
Stroud A, Dhaliwal P, Harvey R, Alvarado R, Jonker B, Winder M Endocr Oncol. 2023; 2(1):19-31.
PMID: 37435446 PMC: 10259300. DOI: 10.1530/EO-21-0026.
Shao C, Wang J, Wang P, Wu N Brain Sci. 2023; 13(4).
PMID: 37190636 PMC: 10137193. DOI: 10.3390/brainsci13040671.
Outcomes of endoscopic transsphenoidal surgery for Cushing's disease.
Brady Z, Garrahy A, Carthy C, OReilly M, Thompson C, Sherlock M BMC Endocr Disord. 2021; 21(1):36.
PMID: 33658018 PMC: 7931517. DOI: 10.1186/s12902-021-00679-9.